Animal models of stroke

Molecular Medicine Today

Volumn 6, Issue 3, 2000, Pages 133-135

  Feuerstein, Giora Z ^a   Wang, Xinkang ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; DIZOCILPINE; FIBRINOLYTIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ANIMAL MODEL; BRAIN BLOOD FLOW; BRAIN PROTECTION; BRAIN TEMPERATURE; CAT; CEREBROVASCULAR DISEASE; EXPERIMENTAL MODEL; GENETIC MODEL; GERBIL; MOUSE; NONHUMAN; PRIMATE; RAT; REVIEW; STROKE;

ANIMALS; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; HUMANS; MONITORING, PHYSIOLOGIC; NEUROPROTECTIVE AGENTS;

ANIMALIA; FELIS CATUS; GERBILLINAE; MALACOTHRIX TYPICA; PRIMATES;

EID: 0034059716     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01643-3     Document Type: Review

References (11)

1. Ginsberg M.D., Busto R. Small animal models of global and focal cerebral ischemia. Ginsberg M.D., Bogousslauvsky J. Cerebrovascular Disease: Pathophysiology, Diagnosis and Management. 1998;14-35 Blackwell Science.
2. Koehler R.C. Large animal models of focal and global ischemia. Ginsberg M.D., Bogousslauvsky J. Cerebrovascular Disease: Pathophysiology, Diagnosis and Management. 1998;36-51 Blackwell Science.
3. Hossmann K.A. Experimental models for the investigation of brain ischemia. Cardiovasc. Res. 39:1998;106-120.
4. Tatlisumak T.et al. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke. 29:1998;1952-1958.
5. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
6. Baron J.C.et al. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke. 26:1995;2219-2221.
7. Coimbra C.et al. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. Stroke. 27:1996;1578-1585.
8. Valtysson J.et al. Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation. Acta Neurochir. 129:1994;58-63.
9. Alkayed N.J.et al. Gender-linked brain injury in experimental stroke. Stroke. 29:1998;159-165.
10. Schulz J.B.et al. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ. 5:1998;847-857.
11. Barone F.C., Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 19:1999;819-834.